SCHEMBL5451815

SCHEMBL5451815

COc1cccc2c1CN(CC(=O)Nc1cccc3c1Cc1ccccc1-3)CC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
MEN1 O00255 4/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 1/20 0.53
POLB P06746 1/20 0.53
PRMT5 O14744 1/20 0.53
WDR77 Q9BQA1 1/20 0.53
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
USP2 O75604 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451592 0.85 L3MBTL1 (0.65) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL5449497 0.84 RECQL (0.65) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5447851 0.79 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL5451485 0.78 LMNA (0.61) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5449816 0.78 DRD2 (0.50) KMT2AMEN1SMN1; SMN2POLBRAB9A
SCHEMBL5753631 0.76 DRD2 (0.53) KMT2AMEN1KDM4EPOLBRAB9A
SCHEMBL5449559 0.76 DRD2 (0.49) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5445261 0.76 NPC1 (0.57) KMT2AMEN1ALDH1A1MAPTPOLB
SCHEMBL5461335 0.75 DRD2 (0.52) KMT2AMEN1KDM4EPOLBRAB9A
SCHEMBL5789543 0.75 KDM4E (0.52) KMT2AMEN1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels IONIX PHARMACEUTICALS LIMITED (GB) 2007-02-22 US disclosed
EP-1660454-A1 AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS Vernalis (R&D) Limited (GB) 2006-05-31 EP disclosed
WO-2005005392-A1 AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS IONIX PHARMACEUTICALS LIMITED (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels SCN1B, SCN1A, SCN10A KMT2A 2911/4885MEN1 2444/4885ALDH1A1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.